kynurenic acid has been researched along with Akinetic-Rigid Variant of Huntington Disease in 20 studies
Kynurenic Acid: A broad-spectrum excitatory amino acid antagonist used as a research tool.
kynurenic acid : A quinolinemonocarboxylic acid that is quinoline-2-carboxylic acid substituted by a hydroxy group at C-4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The brain levels of the endogenous excitotoxin quinolinic acid (QUIN) and its bioprecursor, the free radical generator 3-hydroxykynurenine (3-HK), are elevated in early stage Huntington disease (HD)." | 7.73 | Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. ( Bates, GP; Graham, RK; Guidetti, P; Hayden, MR; Leavitt, BR; MacDonald, ME; Schwarcz, R; Slow, EJ; Wheeler, VC; Woodman, B, 2006) |
| "The brain levels of the endogenous excitotoxin quinolinic acid (QUIN) and its bioprecursor, the free radical generator 3-hydroxykynurenine (3-HK), are elevated in early stage Huntington disease (HD)." | 3.73 | Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. ( Bates, GP; Graham, RK; Guidetti, P; Hayden, MR; Leavitt, BR; MacDonald, ME; Schwarcz, R; Slow, EJ; Wheeler, VC; Woodman, B, 2006) |
| "Boosting KYNA levels, through interference with the KP enzymes or through application of prodrugs/analogs with high bioavailability and potency, is a promising clinical approach." | 2.82 | Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword? ( Ostapiuk, A; Urbanska, EM, 2022) |
| " However, using a comprehensive panel of behavioral tests, we demonstrate that the chronic dosing of a selective KMO inhibitor does not significantly modify behavioral phenotypes or natural progression in mouse models of HD." | 1.43 | The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease. ( Beaumont, V; Bradaia, A; Deisemann, H; Dijkman, U; Dominguez, C; Ebneth, A; Freije, R; Gelman, S; Gleyzes, M; Heikkinen, T; Heins, M; Javier, RM; Khetarpal, V; Kontkanen, O; Lehtimäki, K; Mrzljak, L; Munoz-Sanjuan, I; Neagoe, I; Park, LC; Puoliväli, J; Rassoulpour, A; Steidl, E; Toledo-Sherman, L; Tombaugh, G; Winkler, D, 2016) |
| "Methylene blue (MB), has been shown to modulate aggregation of amyloidogenic disease proteins." | 1.38 | Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models. ( Agrawal, N; Aron, R; Finkbeiner, S; Glabe, C; Lau, A; Lotz, GP; Marsh, JL; Muchowski, PJ; Necula, M; Sontag, EM; Thompson, LM; Tran, A; Yang, G, 2012) |
| " As it did not induce any appreciable side-effect at the protective dose applied in a chronic dosing regime in this mouse model, it appears worthy of further thorough investigations with a view to eventual clinical trials." | 1.37 | Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington's disease. ( Freund, TF; Fülöp, F; Klivényi, P; Nyiri, G; Szatmári, I; Szonyi, A; Toldi, J; Vécsei, L; Zádori, D, 2011) |
| "In a transgenic mouse model of Alzheimer's disease, JM6 prevents spatial memory deficits, anxiety-related behavior, and synaptic loss." | 1.37 | Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. ( Adame, A; Andrews-Zwilling, Y; Flik, G; Giorgini, F; Guidetti, P; Hsieh, EW; Huang, SY; Huang, Y; Laue, G; Lee, J; Louie, JY; Masliah, E; Moussaoui, S; Muchowski, JM; Muchowski, PJ; Notarangelo, FM; Patrick, C; Rassoulpour, A; Sathyasaikumar, KV; Scearce-Levie, K; Schwarcz, R; Truong, J; Wu, HQ; Wu, T; Zwilling, D, 2011) |
| "Probenecid treatment significantly reduced the neuronal loss and the number of neuronal intranuclear aggregates." | 1.35 | Neuroprotective effects of probenecid in a transgenic animal model of Huntington's disease. ( Klivenyi, P; Vamos, E; Vecsei, L; Voros, K; Zadori, D, 2009) |
| "Huntington's disease is a neurological disorder characterised by a progressive chorea and dementia." | 1.28 | Increase in kynurenic acid in Huntington's disease motor cortex. ( Carlà, V; Connick, JH; Moroni, F; Stone, TW, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (10.00) | 18.7374 |
| 1990's | 5 (25.00) | 18.2507 |
| 2000's | 5 (25.00) | 29.6817 |
| 2010's | 6 (30.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ostapiuk, A | 1 |
| Urbanska, EM | 2 |
| Fathi, M | 1 |
| Vakili, K | 1 |
| Yaghoobpoor, S | 1 |
| Tavasol, A | 1 |
| Jazi, K | 1 |
| Hajibeygi, R | 1 |
| Shool, S | 1 |
| Sodeifian, F | 1 |
| Klegeris, A | 1 |
| McElhinney, A | 1 |
| Tavirani, MR | 1 |
| Sayehmiri, F | 1 |
| Beaumont, V | 1 |
| Mrzljak, L | 1 |
| Dijkman, U | 1 |
| Freije, R | 1 |
| Heins, M | 1 |
| Rassoulpour, A | 2 |
| Tombaugh, G | 1 |
| Gelman, S | 1 |
| Bradaia, A | 1 |
| Steidl, E | 1 |
| Gleyzes, M | 1 |
| Heikkinen, T | 1 |
| Lehtimäki, K | 1 |
| Puoliväli, J | 1 |
| Kontkanen, O | 1 |
| Javier, RM | 1 |
| Neagoe, I | 1 |
| Deisemann, H | 1 |
| Winkler, D | 1 |
| Ebneth, A | 1 |
| Khetarpal, V | 1 |
| Toledo-Sherman, L | 1 |
| Dominguez, C | 1 |
| Park, LC | 1 |
| Munoz-Sanjuan, I | 1 |
| Vamos, E | 1 |
| Voros, K | 1 |
| Zadori, D | 2 |
| Vecsei, L | 2 |
| Klivenyi, P | 2 |
| Nyiri, G | 1 |
| Szonyi, A | 1 |
| Szatmári, I | 1 |
| Fülöp, F | 1 |
| Toldi, J | 1 |
| Freund, TF | 1 |
| Campesan, S | 1 |
| Green, EW | 1 |
| Breda, C | 1 |
| Sathyasaikumar, KV | 2 |
| Muchowski, PJ | 3 |
| Schwarcz, R | 6 |
| Kyriacou, CP | 1 |
| Giorgini, F | 2 |
| Zwilling, D | 1 |
| Huang, SY | 1 |
| Notarangelo, FM | 1 |
| Guidetti, P | 5 |
| Wu, HQ | 1 |
| Lee, J | 1 |
| Truong, J | 1 |
| Andrews-Zwilling, Y | 1 |
| Hsieh, EW | 1 |
| Louie, JY | 1 |
| Wu, T | 1 |
| Scearce-Levie, K | 1 |
| Patrick, C | 1 |
| Adame, A | 1 |
| Moussaoui, S | 1 |
| Laue, G | 1 |
| Flik, G | 1 |
| Huang, Y | 1 |
| Muchowski, JM | 1 |
| Masliah, E | 1 |
| Sontag, EM | 1 |
| Lotz, GP | 1 |
| Agrawal, N | 1 |
| Tran, A | 1 |
| Aron, R | 1 |
| Yang, G | 1 |
| Necula, M | 1 |
| Lau, A | 1 |
| Finkbeiner, S | 1 |
| Glabe, C | 1 |
| Marsh, JL | 1 |
| Thompson, LM | 1 |
| Tan, L | 2 |
| Yu, JT | 1 |
| Luthi-Carter, RE | 1 |
| Augood, SJ | 1 |
| Sapko, MT | 1 |
| Yu, P | 1 |
| Tagle, DA | 1 |
| Pellicciari, R | 1 |
| Bates, GP | 1 |
| Graham, RK | 1 |
| Hayden, MR | 1 |
| Leavitt, BR | 1 |
| MacDonald, ME | 1 |
| Slow, EJ | 1 |
| Wheeler, VC | 1 |
| Woodman, B | 1 |
| Perez-De La Cruz, V | 1 |
| Santamaria, A | 1 |
| Jauch, D | 1 |
| Bird, ED | 3 |
| Vonsattel, JP | 1 |
| Whetsell, WO | 1 |
| Harris, CA | 1 |
| Miranda, AF | 1 |
| Tanguay, JJ | 1 |
| Boegman, RJ | 1 |
| Beninger, RJ | 1 |
| Jhamandas, K | 1 |
| Reynolds, GP | 1 |
| Pearson, SJ | 1 |
| Beal, MF | 2 |
| Matson, WR | 2 |
| Storey, E | 1 |
| Milbury, P | 1 |
| Ryan, EA | 1 |
| Ogawa, T | 1 |
| Swartz, KJ | 1 |
| Gamache, PH | 1 |
| Connick, JH | 2 |
| Carlà, V | 2 |
| Moroni, F | 2 |
| Stone, TW | 2 |
4 reviews available for kynurenic acid and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
Topics: Alzheimer Disease; Animals; Brain; Excitatory Amino Acid Antagonists; Humans; Huntington Disease; Ky | 2022 |
Dynamic changes in metabolites of the kynurenine pathway in Alzheimer's disease, Parkinson's disease, and Huntington's disease: A systematic Review and meta-analysis.
Topics: 3-Hydroxyanthranilic Acid; Adenosine; Alzheimer Disease; Humans; Huntington Disease; Hydroxyindoleac | 2022 |
The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Topics: Aging; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Enzyme Inhibitors; Humans; Hunting | 2012 |
Integrative hypothesis for Huntington's disease: a brief review of experimental evidence.
Topics: Animals; Calcium; Cell Death; Disease Models, Animal; Energy Metabolism; Excitatory Amino Acids; Hum | 2007 |
16 other studies available for kynurenic acid and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Analysis of Variance; Animals; Brain; Disease Models, Anima | 2016 |
Neuroprotective effects of probenecid in a transgenic animal model of Huntington's disease.
Topics: Age Factors; Animals; Cell Count; Chromatography, High Pressure Liquid; Disease Models, Animal; Dose | 2009 |
Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Excitatory Amino Acid Antagonists; Female; Humans; | 2011 |
The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease.
Topics: Animals; Animals, Genetically Modified; Disease Models, Animal; Drosophila melanogaster; Huntington | 2011 |
Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration.
Topics: Administration, Oral; Alzheimer Disease; Animals; Brain Chemistry; Disease Models, Animal; Female; H | 2011 |
Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models.
Topics: Analysis of Variance; Animals; Brain-Derived Neurotrophic Factor; Cells, Cultured; Cerebral Cortex; | 2012 |
Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease.
Topics: Aged; Analysis of Variance; Cerebellum; Cerebral Cortex; Frontal Lobe; Humans; Huntington Disease; K | 2004 |
Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease.
Topics: Animals; Brain Chemistry; Excitatory Amino Acid Agonists; Huntington Disease; Kainic Acid; Kynurenic | 2006 |
Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice.
Topics: Age Factors; Animals; Brain Chemistry; Chromatography, Gas; Chromatography, High Pressure Liquid; Di | 2006 |
Dysfunction of brain kynurenic acid metabolism in Huntington's disease: focus on kynurenine aminotransferases.
Topics: Aged; Brain; Brain Chemistry; Female; Humans; Huntington Disease; Kinetics; Kynurenic Acid; Lyases; | 1995 |
Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid.
Topics: Alanine; Animals; Anticonvulsants; Corpus Striatum; Dose-Response Relationship, Drug; Drug Synergism | 1998 |
Neurochemical abnormalities in Huntington's disease: neurotoxic mechanisms and neurotransmitter changes.
Topics: Brain Chemistry; Humans; Huntington Disease; Kynurenic Acid; Neurotransmitter Agents | 1992 |
Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex.
Topics: Aged; Alzheimer Disease; Cerebral Cortex; Energy Metabolism; Free Radicals; Humans; Huntington Disea | 1992 |
Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid.
Topics: Aged; Autopsy; Corpus Striatum; Female; Humans; Huntington Disease; Kynurenic Acid; Kynurenine; Male | 1990 |
Increase in kynurenic acid in Huntington's disease motor cortex.
Topics: Aged; Caudate Nucleus; Frontal Lobe; Globus Pallidus; Humans; Huntington Disease; Kynurenic Acid; Mi | 1989 |
Increased kynurenic acid levels in Huntington's disease.
Topics: Brain Chemistry; Humans; Huntington Disease; Kynurenic Acid | 1988 |